Tech Company Financing Transactions
Rgenta Therapeutics Funding Round
On 4/6/2020, Rgenta Therapeutics landed $20 million in Seed funding from Boehringer Ingelheim Venture Fund, Matrix Partners and Kaitai Capital.
Transaction Overview
Company Name
Announced On
4/6/2020
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Seed
Investors
Boehringer Ingelheim Venture Fund (Lead Investor) (Martin Heidecker)
Matrix Partners (Lead Investor)
Proceeds Purpose
With their support, we will be able to rapidly advance our lead RNA-targeting programs into preclinical studies and expand our portfolio to pursue high-value RNA targets in a range of therapeutic areas.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St. LabCentral
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Simon Xi
Chief Scientific Officer
Travis Wager
Browse more venture capital transactions:
Prev: 4/4/2020: OctoML venture capital transaction
Next: 4/6/2020: Tailscale venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs